Biotech company nabs top two floors at Vornado's Penn 1 [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
Roivant Sciences will take the 55,000-square-foot duplex penthouse at the Midtown tower, a source said. The firm will occupy the entire 54th and 55th floors, moving from Durst Organization's 151 West 42nd Street. The 15-year lease's asking rent was $140 per square foot, according to a source familiar with the deal. A Newmark team including Neil Goldmacher and Josh Friedman represented Roivant, while Vornado was represented in-house by a team including Josh Glick and Jared Silverman. Ramaswamy founded Roivant in 2014 and stepped down last year from the company's board to focus on his campaign. He dropped out of the race in January after finishing fourth in the Iowa caucuses. The firm did not immediately respond to a request for comment on the lease. Vornado, led by Steven Roth, poured $450 million into Penn 1, formerly known as 1 Pennsylvania Plaza, to improve the property's 55 floors. Updates at the 2.5-million-square-foot complex included new plazas, a curtain wall, refres
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Is Roivant Sciences Ltd. (ROIV) a Strong Buy Amid Positive Clinical Trials and Strategic Partnerships? [Yahoo! Finance]Yahoo! Finance
- Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%GlobeNewswire
ROIV
Earnings
- 8/8/24 - Beat
ROIV
Sec Filings
- 10/1/24 - Form 4
- 9/26/24 - Form 4
- 9/26/24 - Form 4
- ROIV's page on the SEC website